Color vision testing is an important clinical skill for ophthalmic assistants. It is used to screen for congenital color deficiencies, monitor acquired color changes from retinal disease or medication toxicity, and qualify patients for occupations requiring specific color discrimination. On the COA exam, color vision testing falls within the Assessments domain, which represents 42% of the exam.
This guide covers the two most clinically important tests — the Ishihara pseudoisochromatic plates and the Farnsworth D-15 — along with the classification of color deficiencies, proper administration technique, and the clinical scenarios where color vision testing matters most.
Understanding Color Vision and Deficiency
Normal human color vision (trichromacy) relies on three types of cone photoreceptors in the retina, each sensitive to different wavelengths of light: long-wavelength cones (L, sensitive to red), medium-wavelength cones (M, sensitive to green), and short-wavelength cones (S, sensitive to blue). Color vision deficiencies arise when one or more cone types is absent, reduced in number, or has abnormal spectral sensitivity.
| Condition | Cone Affected | Severity | Prevalence (Males) |
|---|---|---|---|
| Deuteranomaly | M cone (shifted sensitivity) | Mild-moderate green weakness | ~5% |
| Deuteranopia | M cone (absent) | Green blindness | ~1% |
| Protanomaly | L cone (shifted sensitivity) | Mild-moderate red weakness | ~1% |
| Protanopia | L cone (absent) | Red blindness | ~1% |
| Tritanomaly | S cone (shifted sensitivity) | Blue-yellow weakness | <0.01% |
| Tritanopia | S cone (absent) | Blue-yellow blindness | <0.01% |
| Achromatopsia | All cones | Complete color blindness | ~0.003% |
COA Exam Key Fact
Color vision deficiency follows an X-linked recessive inheritance pattern for red-green types. This explains why it is far more common in males (~8% of males, ~0.5% of females). Blue-yellow deficiencies are autosomal dominant and affect males and females equally.
Ishihara Pseudoisochromatic Plates
The Ishihara pseudoisochromatic plates, first published in 1917, are the most widely used color vision screening tool in clinical practice. Each plate contains a circular field of colored dots in which a number or line is embedded. The number is visible to people with normal color vision but appears as random dots to those with specific color deficiencies — or vice versa (some plates are designed to be read only by color-deficient individuals).
38
Full test plates
14-plate screening version commonly used
75 cm
Testing distance
~30 inches from patient
3 sec
Per plate limit
Prevent guessing; enforce timing
Plate Types in the Ishihara Test
Transformation plates
Normal observers read one number; color-deficient observers read a different number. These reveal not just that a deficiency exists, but the type.
Vanishing plates
Normal observers see the number; color-deficient observers see nothing. These confirm the presence of deficiency but do not classify it precisely.
Hidden digit plates
Color-deficient observers see the number; normal observers see nothing. Useful for confirming that a patient is not malingering or guessing correctly on other plates.
Diagnostic plates
Late plates in the full 38-plate set that help distinguish protan (red) from deutan (green) defects by comparing what the patient reads.
Farnsworth D-15 Panel Test
The Farnsworth-Munsell D-15 (Dichotomous 15) test presents 15 removable colored caps (plus one fixed reference cap) arranged in a circular hue sequence. The patient arranges the 15 caps in order of most similar hue, starting from the reference. In a normal observer, the arrangement follows the natural color circle sequence. In a color-deficient observer, characteristic error patterns emerge that reveal the type and axis of the deficiency.
The D-15 is particularly valuable for detecting moderate-to-severe color deficiencies and for identifying acquired color defects — those caused by ocular disease or medication toxicity — because it can detect both red-green and blue-yellow axes of confusion. Acquired deficiencies (from glaucoma, macular degeneration, optic neuropathy) often show a blue-yellow (tritan) confusion axis even in patients who have never had a hereditary color problem.
Ishihara: Best For
- Rapid red-green deficiency screening
- Occupational and school screening
- Detecting X-linked congenital defects
- Routine clinical practice (quick to administer)
Farnsworth D-15: Best For
- Classifying defect type and severity
- Detecting blue-yellow acquired defects
- Monitoring drug toxicity (hydroxychloroquine)
- Detecting early glaucomatous color changes
Practice COA Questions
Opterio covers color vision testing and all other COA assessment skills. AI-powered explanations clarify the clinical reasoning behind each answer.
Clinical Significance of Color Vision Testing
Glaucoma Monitoring
Glaucomatous damage to the optic nerve frequently produces a blue-yellow color deficiency that can precede detectable visual field loss. Color vision testing can be a sensitive early indicator of progression in glaucoma patients between visual field tests.
Drug Toxicity Screening
Hydroxychloroquine (Plaquenil), used in rheumatoid arthritis and lupus, can cause macular toxicity. Early toxicity is associated with color vision changes — particularly blue-yellow defects detected by the D-15. Baseline color vision testing before starting treatment and periodic monitoring are recommended by the American Academy of Ophthalmology.
Optic Neuritis
Optic neuritis from multiple sclerosis or other causes typically produces profound color desaturation — colors appear washed out or reduced in intensity — often before major VA loss. Patients may describe red objects looking faded or gray. This "dyschromatopsia" is a hallmark symptom and a key clinical observation to document.
Occupational Screening
Pilots, certain military positions, electricians, and other professions require specific minimum color vision standards. Ophthalmology offices frequently perform color vision testing for occupational purposes. The Ishihara plates are the standard tool for these assessments, and the pass criteria are defined by each regulatory body.